Institut für Medizinische Informatik, Biometrie und Epidemiologie, Universität Duisburg-Essen, Essen, Germany.
Klinik für Hämatologie, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Germany.
Cancer Med. 2024 Apr;13(7):e7095. doi: 10.1002/cam4.7095.
Information about follow-up care in blood cancer survivors is limited. The questionnaire-based "Aftercare in Blood Cancer Survivors" (ABC) study aimed to identify patterns of follow-up care in Germany and compare different types of follow-up institutions.
The study's 18-month prospective part compared the follow-up institutions identified in the preceding retrospective part (academic oncologists, community oncologists, primary care physicians). The questionnaires were completed by the follow-up physicians.
Of 1070 physicians named by 1479 blood-cancer survivors, 478 (44.7%) consented to participate. For provision of care, most oncologists relied on published guidelines, while most primary care physicians depended on information from other physicians. Survivors with a history of allogeneic transplantation or indolent lymphoma were mainly seen by academic oncologists, whereas survivors with monoclonal gammopathy, multiple myeloma, or myeloproliferative disorders were often seen by community oncologists, and survivors with a history of aggressive lymphoma or acute leukemia by primary care physicians. Detection of relapse and secondary diseases was consistently viewed as the most important follow-up goal. Follow-up visits were most extensively documented by academic oncologists (574 of 1045 survivors cared for, 54.9%), followed by community oncologists (90/231, 39.0%) and primary care physicians (51/203, 25.1%). Relapse and secondary disease detection rates and the patients' quality of life were similar at the three institutions. Laboratory tests were most often ordered by academic oncologists, and imaging by primary care physicians. Psychosocial issues and preventive care were more often addressed by primary care physicians than by oncologists.
Patients at high risk of relapse or late complications were preferentially treated by academic oncologists, while patients in stable condition requiring continuous monitoring were also seen by community oncologists, and patients with curable diseases in long-term remission by primary care physicians. For the latter, transfer of follow-up care from oncologists to well-informed primary care providers appears feasible.
有关血液癌幸存者后续护理的信息有限。基于问卷的“血液癌幸存者后续护理(ABC)”研究旨在确定德国的后续护理模式,并比较不同类型的后续护理机构。
该研究的 18 个月前瞻性部分比较了前一个回顾性部分确定的后续护理机构(学术肿瘤学家、社区肿瘤学家、初级保健医生)。由后续医生填写问卷。
在 1479 名血液癌幸存者提名的 1070 名医生中,有 478 名(44.7%)同意参与。在提供护理方面,大多数肿瘤学家依赖于已发表的指南,而大多数初级保健医生则依赖于其他医生的信息。接受过同种异体移植或惰性淋巴瘤治疗的幸存者主要由学术肿瘤学家诊治,而患有单克隆丙种球蛋白病、多发性骨髓瘤或骨髓增生性疾病的幸存者通常由社区肿瘤学家诊治,患有侵袭性淋巴瘤或急性白血病史的幸存者则由初级保健医生诊治。检测复发和继发性疾病始终被视为最重要的后续目标。学术肿瘤学家对随访就诊记录最全面(1045 名接受治疗的幸存者中的 574 名,54.9%),其次是社区肿瘤学家(231 名中的 90 名,39.0%)和初级保健医生(203 名中的 51 名,25.1%)。在这三个机构,复发和继发性疾病的检出率和患者的生活质量相似。学术肿瘤学家最常开实验室检查,初级保健医生最常开影像学检查。初级保健医生比肿瘤学家更常处理心理社会问题和预防保健。
高复发风险或晚期并发症的患者优先由学术肿瘤学家治疗,而病情稳定需要持续监测的患者也由社区肿瘤学家治疗,处于长期缓解期的可治愈疾病患者则由初级保健医生治疗。对于后者,将随访护理从肿瘤学家转移到知情的初级保健提供者似乎是可行的。